Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours

Avishai Gavish, Michael Tyler, Alissa Greenwald, +25

Nature

Tumor HeterogeneityThousand TumoursMedicineCancer GenomicsCancer Biology +3

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice

Rouven Hoefflin, Sabine Harlander, Silvia Schäfer, +22

Nature Communications

Integrative spatial analysis reveals a multi-layered organization of glioblastoma

Alissa Greenwald, Noam Galili Darnell, Rouven Hoefflin, +20

Cell

Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience

Rouven Hoefflin, Anna-Lena Geißler, Ralph Fritsch, +30

JCO Precision Oncology

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity

Rouven Hoefflin, Bernd Lahrmann, Gregor Warsow, +26

Nature Communications

Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

Rouven Hoefflin, Adriana Lazarou, Maria Elena Hess, +40

Cancers

Surgical OncologyClinical RoutineMtb PatientsCancer ManagementPathology +20

A spatial expression atlas of the adult human proximal small intestine

Yotam Harnik, Oran Yakubovsky, Rouven Hoefflin, +19

Nature

Gross AnatomyFood DigestionPhysiologyGastroenterologyPathology +7

Integrative spatial analysis reveals a multi-layered organization of glioblastoma

Alissa Greenwald, Noam Galili Darnell, Rouven Hoefflin, +16

Summary GliomaBiological MicroenvironmentsSpatial OmicsGliomaTumor Biology +17

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response

Petya Apostolova, Stefanie Kreutmair, Cristina Toffalori, +32

British Journal of Haematology

ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma

Philipp Seidel, Anne Rubarth, Kyra Zodel, +18

JCI Insight

Chemoprevention StrategyImmunologyKinase InhibitorsPathologyHuman Ccrccs +14